Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a company dedicated to pushing the boundaries of biopharmaceutical innovations, is making news with its decision to implement a 1-for-8 reverse stock split of its outstanding common stock. This strategic decision is set to take effect when trading begins on an upcoming Monday.
Reason Behind the Reverse Stock Split
Sonnet BioTherapeutics aims to raise the trading price of its common stock through this reverse stock split. The company is striving to meet the $1.00 minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market, as specified in Rule 5550(a)(2). Following the split, shares will still be traded under the symbol “SONN,” but they will be associated with a new CUSIP number.
Effects on Shareholders
The reverse stock split will significantly reduce the number of outstanding shares. Specifically, the number of Sonnet’s shares will go from about 5.2 million to roughly 650,300. Importantly, the par value for each share will remain at $0.0001, and the total number of authorized shares will not change as a result of this split.
How Shares Will Be Adjusted
Under this reverse stock split, every eight shares held before the split will combine into one share. While this change will impact all shareholders, it’s worth noting that fractional shares won't be issued. Any shareholder entitled to a fractional share will receive a cash payment based on the average closing price of the stock over the five trading days leading up to the split's effective date.
Adjustments for Warrants and Options
This reverse stock split will also affect all common stock available through Sonnet’s existing warrants and stock options. Consequently, adjustments will be made to the exercise prices of these warrants and options to ensure that their holders are treated fairly.
Approval Process for the Split
In mid-September, the majority of shareholders approved this strategic initiative, granting Sonnet's board the authority to choose a split ratio within a certain range. The board finalized the decision to proceed with a 1-for-8 ratio in late September.
Resources for Shareholders
Securities Transfer Corporation has been appointed as the exchange agent and transfer agent to facilitate the reverse stock split. Shareholders who hold their shares in book-entry form or in brokerage accounts don't need to take any further action during this process. Anyone with questions should reach out to their bank or broker for assistance.
Innovative Moves by Sonnet BioTherapeutics
Sonnet BioTherapeutics isn't just focused on financial strategies; it's also making notable progress in oncology. This biotechnology firm is utilizing an innovative platform to create new biologic therapeutics that feature single or bifunctional actions. Their unique technology, called FHAB (Fully Human-Albumin Binding), employs a fully human single-chain antibody fragment that enhances targeting of tumor cells.
Looking Ahead
Sonnet BioTherapeutics' pipeline follows a modular approach for large molecule therapeutics, allowing potential integration of cytokines, peptides, antibodies, and vaccines into its treatment strategies—ultimately leading to better options in cancer therapy.
Frequently Asked Questions
What is the purpose of Sonnet's reverse stock split?
The reverse stock split is meant to raise the company's common stock price to comply with Nasdaq listing requirements.
What happens to shareholders' shares after the split?
After the split, shareholders will receive one new share for every eight shares they previously held, which will significantly reduce the total outstanding shares.
Will fractional shares be issued?
No, fractional shares won't be issued. Instead, shareholders entitled to a fractional share will receive a cash payment.
Who can I contact for questions about my shares?
Shareholders should contact their bank, broker, or custodian for assistance with any questions about their shares during this transition.
What innovations is Sonnet pursuing in oncology?
Sonnet BioTherapeutics is focused on creating advanced biologic drugs using its FHAB technology, which effectively targets cancer through improved delivery of therapeutics.
